The Index
400 dossiers · 1 need attention
A research screener for every company we cover. Search a name or ticker, then sort and triage dossiers by coverage freshness, our conviction and trading relevance.
| The safest, most surgically scalable path into the brain and the only BCI Apple made a native input — but it bet the company on "good enough" 16-electrode bandwidth, and its own third-gen "whole-brain" pivot is a confession that the moat it is famous for may be the ceiling it has to escape. | — | 8 | |
| The only FDA-cleared, commercially-shipping cortical BCI — but it is selling a 30-day surgical-monitoring tool, not the chronic implant the $500M valuation is priced on; Medtronic is the real tell, IP overhang from Rapoport's Neuralink past is the real risk. | — | 8 | |
| The highest-bandwidth intracortical BCI just put its wireless device in a human brain (17 Jun 2026) — but it is two patients into an EFS, ~3-5 years from revenue, and out-capitalized ~3-4:1 by Neuralink, so the bet is "bandwidth wins the speech-prosthesis category" against a far better-funded field. | — | 8 | |
| The category's brand and bandwidth leader, but the bet is binary on durable signal-at-scale and CMS reimbursement — not yet a tradeable security, and the moment a Synchron or Precision reaches a pivotal trial first, Neuralink's "lead" is narrative, not regulatory. | — | 8 | |
| A blueberry-sized, battery-free epidural stimulator with a Medtronic-grade team and a clean FDA IDE — but it is a single-asset, sub-$30M minnow in a field of nine-figure whales, and its closest peer (Inner Cosmos) already has the clinical lead. | — | 0 | |
| The most-implanted BCI on Earth and the worst-capitalized relative to its peers — a 2008-era electrode bet now owned by a stablecoin issuer, where the moat is two decades of human data and the kill-switch is glial scar tissue. Watching, not buying, until a De Novo/PMA submission and a clean secondary mark say the Tether money actually bought commercialization rather than just runway. | — | 0 |